Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies. Issue 1 (January 2019) - Orkin, C.